Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT00425932 Completed - Clinical trials for Rheumatoid Arthritis

Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

Start date: February 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further investigate rituximab in the treatment of rheumatoid arthritis and to evaluate magnetic resonance imaging of the joints as a possible method to improve the evaluation of treatments.

NCT ID: NCT00425321 Completed - Clinical trials for Rheumatoid Arthritis

Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the safety and tolerability of 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with active Rheumatoid Arthritis despite methotrexate therapy.

NCT ID: NCT00424502 Completed - Clinical trials for Rheumatoid Arthritis

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

Start date: January 2007
Phase: Phase 4
Study type: Interventional

This single arm study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis whose current treatment with one or more TNF blocker had produced an inadequate response. Patients will receive MabThera (1g infusion) on day 1 and day 15, and will continue on their basic methotrexate therapy (10-25mg/week). The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.

NCT ID: NCT00424346 Completed - Clinical trials for Rheumatoid Arthritis

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The 12-week core study was designed to evaluate risk-benefit of three subcutaneous dose regimens of ACZ885, added on to stable methotrexate (MTX) therapy (greater than or equal to 7.5 mg/week), compared to placebo in patients with active rheumatoid arthritis (RA). The study investigated the magnitude of effect as well as onset of effect for the different dose regimens. The primary objective of the extension studies was to assess long-term safety and tolerability of canakinumab (ACZ885) in patients with active RA. CACZ885A2201E1 evaluated this objective in patients who had participated in the core study (CACZ885A2201) and CACZ885A2201E2 did the same in patients who completed the first extension study.

NCT ID: NCT00423358 Completed - Clinical trials for Rheumatoid Arthritis

Treatment of Hypovitaminosis D in Rheumatoid Arthritis

Start date: February 2005
Phase: N/A
Study type: Interventional

This study recruits individuals with rheumatoid arthritis (RA) and low vitamin D concentrations. Subjects are dosed with vitamin D or placebo for one year. Primary outcome is change in bone turnover markers, additionally, bone mineral density and parameters of RA status are evaluated throughout the study.

NCT ID: NCT00422383 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)

Start date: February 2006
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of various treatment and retreatment regimens of MabThera. All patients will receive concomitant methotrexate, 10-25mg once weekly either orally or parenterally. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.

NCT ID: NCT00422227 Completed - Clinical trials for Rheumatoid Arthritis

Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

Start date: June 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia Pacific region.

NCT ID: NCT00420927 Completed - Clinical trials for Rheumatoid Arthritis

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

OPTIMA
Start date: December 2006
Phase: Phase 4
Study type: Interventional

This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).

NCT ID: NCT00413452 Completed - Clinical trials for Rheumatoid Arthritis

Etanercept SFP in RA Patients

Start date: December 2006
Phase: Phase 3
Study type: Interventional

Purpose of this study is to evaluate the immunogenicity and overall safety of etanercept SFP therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.

NCT ID: NCT00412399 Completed - Clinical trials for Rheumatoid Arthritis

Job Adaptation in Patients With Rheumatoid Arthritis

Start date: June 1999
Phase: N/A
Study type: Observational

The specific aim of this study is to compare the rate of negative work role events in individuals with rheumatoid arthritis compared to healthy controls.